Perspective on biotech

Blue Latitude Health | 14th September 2017

Biotech companies operate in highly complex markets with extremely challenging regulatory constraints. As a creative marketing consultancy we are well positioned to cut through this noise and tackle challenges from all angles, offering leading strategic and creative solutions. 

Ahead of our upcoming report into strategic challenges and opportunities in the sector, we have been speaking to biotech experts to find out their perspective on the state of the industry. 

Here we explore some of their enlightening insights and reveal how the definition of biotech is changing as big pharma turns its research and development to biological therapies. 

Find out about: 

  • The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques
  • How to define a biotech company – is the current definition still valid?
  • Shaping the future of healthcare – solving four common challenges facing biotech companies today.

 

What does programmatic advertising mean for your pharma marketing strategy?

Jiayi Chen | 11th January 2018

Senior Associate Consultant Jiayi Chen explains the benefits and pitfalls of programmatic advertising and reveals how it can impact return on investment in your marketing campaigns.

 

read more

How to measure marketing success: profit vs ROI

Paul Townley-Jones | 4th January 2018

Measuring marketing activity is proving to be a major challenge in pharma. Here, Senior Consultant Paul Townley-Jones explores the meaning of success and gives his tips for measuring efficiency and effectiveness, along with the formula for calculating profit and ROI.

read more

Warning signs: making the most of multichannel marketing

Chris Ross | 5th December 2017

Pharma is making measured progress in its adoption of multichannel marketing. But can it actually measure success? And does it even know what good looks like? Chris Ross interviews Senior Consultant Paul Towney Jones to explore the risks and benefits of increased investment in MCM.

read more